Monday, Apr 11, 1994
Dublin -- April 11, 1994 --The first new treatment approach in 30 years specifically developed for cystic fibrosis (CF) patients was introduced today in Ireland with the launch of Pulmozyme® (dornase alfa).
The most common fatal genetic disease in Caucasians, CF affects 1,000 people in Ireland out of the more than 20,000 people in Europe who have the disease. The median age of survival is 25 years.
Pulmozyme was developed by Genentech, Inc. and will be marketed in Ireland under a collaborative agreement with F. Hoffman-La Roche Ltd.
Pulmozyme was unanimously recommended for approval by the CPMP (Committee for Proprietary Medicinal Products) on December 17, 1993. It has already been approved for marketing in the United States, Canada, Austria, Sweden, Denmark, Argentina and the United Kingdom. Approval is expected shortly in other European countries.
Genentech, Inc. is a leading international biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Genentech Europe Ltd., based in Basle, Switzerland, is a subsidiary of Genentech, Inc. of South San Francisco, California, USA and was formed for the clinical development and distribution of Genentech products in Europe.
# # #